



May 29, 2023

To

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 - 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Publication of Extract of Financial Results in an English national daily newspaper

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Friday, 26th May 2023, published in 'The Economic Times', an English national daily newspaper, the extract of the Financial Results for the quarter and the year ended 31st March 2023. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

For Aragen Life Sciences Limited

KASTURI
RAMAKRIS
HNA

Digitally signed by
KASTURI
RAMAKRISHNA
Date: 2023.05.29
10:33:02 +05'30'

Ramakrishna Kasturi

Company Secretary & Compliance Officer

Motherhood Looks to Double Natal Care Capacity

Mrunmayee Kulkarni
@timesgroup.com

Bangalore: PE-backed women and child-focused healthcare chain Motherhood Hospital is looking to double its neonatal intensive care unit (NICU) capacity in the next two years.

The Asia Healthcare Holdings (AHH), the holding company of the hospital chain, which operates 23 hospitals in 11 cities, is planning to scale up with some buyouts, its Executive Chairman Vishal Ballal told ET. Motherhood, according to him, has added 300 NICU beds over

the last three years. The hospital chain launched NICU Live - a remote patient monitoring model - in April this year, bringing the total number of beds to 500. "We are now the largest neonatology network in the country."

Motherhood has had major acquisitions over the past year - Feminit in Bengaluru and Chhatanya in the Tricity region of Mohali and Chandigarh. All of the acquisitions were funded with re-

sources at hand and were immediately accretive, said Ball. The hospital chain is targeting a revenue of around ₹750 crore in fiscal year 2023-24. The hospital is estimated to have ended the last fiscal year with about ₹50 crore in revenues.

Ball was earlier the CEO of Wockhardt Hospitals, and of Fortis Healthcare after the former sold 10 of its hospitals to the latter.

AHH, the chairman said, was exclusively focused on building single-specialty hospital chains, rather than multi-specialty.

"We have found that focusing on a single specialty is much more prof-

itable in terms of scalability. Also, we are able to provide higher domain expertise and clinical distinction than a multi-specialty hospital," said Ball.

The group is looking to explore more specialties like Gastroenterology, Pathology diagnostics and Urology he added. Right now, the group owns Nova IVF fertility centre, with 62 units in 42 cities, along with Motherhood.

The AHH is backed by the private equity fund TPG Growth and Singapore's sovereign wealth fund GIC. TPG Growth has a 35% stake in the company, while GIC owns 45%.

DS Group's Resolution Plan for Viceroy Hotels Gets NCLT Nod

Maulik Vyas
@timesgroup.com

Mumbai: The Hyderabad bench of the National Company Law Tribunal (NCLT) has approved Dharampal Satyapal Group's resolution plan for Viceroy Bangalore Hotels.

The hospitality company owns the Marriott-managed Grand Residency Bengaluru, Chaturu Race Course Hotel, and has around ₹1,100 crore of un-

paid debt.

The New Delhi-based acquirer has proposed ₹300 crore to buy the company in a court-monitored insolvency resolution process.

"The resolution plan along with annexures and schedules forming part of the plan shall be binding on the corporate debtor, its employees, members, creditors," observed the bench led by Justice Rajanji Kelkar and Chauru Singh in its order of May 22.

Steelcase
SIT BETTER. WORK BETTER.



SEATING WORLD
+91 9502499088, +91 8886220005
www.seatingworldindia.com

Pulmonary Hypertension

Turaga Sai Subha

Pulmonary hypertension is one of the most undiagnosed diseases in the field of medicine today. The word 'hypertension' usually is understood to be systemic hypertension where the blood pressure throughout the body is high. However, very less people are aware about hypertension being of two types and the second type being pulmonary hypertension - where the pressure in the pulmonary arteries is increased causing damage in the lungs and right side of the heart.

Thus, to spread awareness about this second type of hypertension called pulmonary hypertension, The Times of India in association with MSN Laboratories conducted a webinar with a panel of senior doctors from Hyderabad city including Dr Nitin Rao, chief paediatric cardiologist, Star Hospitals, Dr Murli Mehra, consultant pulmonologist, Renova Hospitals, Dr Rajeev Garg, senior interventional cardiologist, Dr Bhanu Kiran Reddy, consultant cardiologist, SLG Hospitals, Dr Raghunath Reddy, pulmonologist and sleep medicine specialist.

Explaining about pulmonary hypertension, Dr Nitin Rao shared, "Lungs also have their own role to play in keeping the blood pressure in safe numbers. Normally, the pressure in the pulmonary arteries are 25mm Hg when at rest and 30mm Hg after exercise. But when the

Know about this second type of hypertension

Obesity can be one of the leading lifestyle factors that contribute to developing PH, say experts while suggesting patients to maintain a healthy BMI to be able to control the complications better



pressure in the arteries that pump deoxygenated blood from the heart to the lungs increases from the normal, it is called PH. This can be caused due to many factors - prominent ones being heart and lung diseases.

"Obesity is one of the highest risk factors for developing PH. And the second category of people who can be at high risk for PH are those who use illicit drugs. People with familial history of PH, who live in high altitudes or highly polluted areas can be more prone to develop PH. Also, women between the age of 30-60 are at a higher risk. The incidents of PH are on the rise and it accounts for about 10 per cent of cases over the age of 65," Dr Rajeev shared.

When the patient doesn't show any cause for PH even after certain examinations, it becomes important to study the familial history of the patient to check if there are chances for it to be passed through heredity. The three generations of the patient are examined through counselling and genetic examinations, Dr Bhanu Kiran Reddy mentioned.

On the various factors that cause PH, Dr Raghunath Reddy revealed, "Chronic lung problems such as COPD, severe asthma, bronchitis

artery, then CT pulmonary angiography can be performed to know the size of pulmonary arteries and its branches, and also know the type of PH. After that, we have pulmonary function test which helps us understand how much damage has been occurred. We also test the patient's capacity with a 6-minute walk test - if the patient is able to walk more than 400 m, it is okay otherwise, in PH patients, it is less than 300 m. This capacity keeps on decreasing if it is not treated."

"Pulmonary ventilation/perfusion scan scan of the lungs is also done in some cases to know the damage in the lungs in the form of clots and if perfusion is happening in the lungs. It also helps determine if the patient is having enough saturation to carry-on the normal oxygenation of the blood and the brain. Then we have echocardiogram which measures the right ventricle and pulmonary arterial pressure by terms of a Doppler. Cardiac MRI and lastly, right heart catheterization are suggested for diagnosis of PH," he added.

The experts mentioned that early diagnosis of PH and the treatment of the underlying cause can bring down the pulmonary arterial pressures.

—Please write to dipal.gala@timesgroup.com for any comments on the report.

SATYA MicroCapital Ltd.
सर्व मन्वु प्लिन

(CIN: U74999DL1999PLC048888)
Registered Office Address: 515, 5th Floor, DL Prime Towers, Old Industrial Area, Phase-1, New Delhi-110020
Phone No. 011-49724000 | Website: www.satymicrocapital.com

EXTRACT OF THE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

S.No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
1.	Total Income from operations	2622.19	1458.84	7360.46	4015.41	738.04	4017.80		
2.	Net Profit for the period (Before Tax, Exceptional and/or Extraordinary Items)	524.16	251.88	714.11	435.09	715.81	434.87		
3.	Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	524.16	261.89	714.11	435.09	715.81	434.87		
4.	Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	390.21	195.20	530.44	325.03	531.28	324.81		
5.	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	385.55	195.55	525.61	324.29	525.45	324.07		
6.	Paid up Equity Share Capital			593.20	490.64	593.20	490.64		
7.	Instruments entirely equity in nature			49.00	29.85	49.00	29.85		
8.	Reserves (excluding Revaluation Reserve)			975.34	448.44	966.11	448.22		
9.	Securities Premium Account			6,754.05	4,853.74	6,754.05	4,853.74		
10.	Net worth			8,372.59	5,527.67	8,362.36	5,523.45		
11.	Paid up Debt Capital/ Outstanding Debt			36,664.05	22,772.25	36,664.05	22,772.25		
12.	Outstanding Redeemable Preference Shares			Nil	Nil	Nil	Nil		
13.	Debt Equity Ratio (no. of times)			4.38	4.13	4.38	4.13		
14.	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)								
1.	Basic	7.58	4.21	10.56	7.05	10.57	7.05		
2.	Diluted	6.83	4.13	9.60	6.94	9.61	6.94		
15.	Capital Redemption Reserve			Nil	Nil	Nil	Nil		
16.	Debiture Redemption Reserve			3.69	Nil	3.69	Nil		
17.	Debt Service Coverage Ratio			NA	NA	NA	NA		
18.	Interest Service Coverage Ratio			NA	NA	NA	NA		

*The EPS and DPS for quarter ended March 31, 2023 and March 31, 2022 are not annualised

Disclosure in compliance with Regulation 52(a) of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015 (as amended) for the year ended March 31, 2023 are presented in below table:

S.No.	Particulars	Standalone	Consolidated	S.No.	Particulars	Standalone	Consolidated
		Year Ended March 31, 2023	Year Ended March 31, 2023			Year Ended March 31, 2023	Year Ended March 31, 2023
1.	Net profit after tax (₹ in million)	520.44	521.20	8.	Debtors turnover	NA	NA
2.	Earnings per share			9.	Inventory turnover	NA	NA
3.	Basic (not annualised)	10.56	10.57	10.	Operating margin (%)	NA	NA
4.	Diluted (not annualised)	9.60	9.61	11.	Net profit margin (%)	7.21%	7.19%
5.	Current ratio (no. of times)	NA	NA	Sector specific equivalent ratios, as applicable:			
6.	Long term debt to working capital (no. of times)	NA	NA	12.	OPRA (%)	1.29%	NA
7.	Bad debts to account receivable ratio	NA	NA	13.	NMFA (%)	0.47%	NA
8.	Current liability ratio (no. of times)	NA	NA	14.	CRAR (%)	19.23%	NA
9.	Total debts to total assets	0.79	0.79				

Notes:

- The above financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 24, 2023 in accordance with the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended). The financial results for March 31, 2023 have been audited by the statutory auditor in compliance with Ind AS as notified by Ministry of Corporate Affairs and the published unaudited report.
- The above is an extract of the detailed format of financial results for the quarter and year ended March 31, 2023 filed with the Stock Exchange of India Limited under Regulation 52 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the financial results in terms of Regulation 52 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 for the quarter and year ended March 31, 2023 are also available on the website of SEBI Limited at www.sebiindia.com and on the website of the Company at www.satymicrocapital.com.
- This report of financial results for the quarter and year ended March 31, 2023 has been prepared in accordance with the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with operational circulars SEBI/HO/CFD/CIR-1/P/2022/000001 dated July 29, 2022.

For and on behalf of the Board of Directors of SATYA MicroCapital Limited

S/ Virek Tiwari
Managing Director, CEO and CFO
DIN: 0317410

Place: Gurugram
Date: May 24, 2023

ARAGEN LIFE SCIENCES LIMITED
(formerly known as Aragen I life Sciences Private Limited)
CIN: U74999TG2000PLC035826

Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad
Telangana-500076, India, Tel: +91 40 6692 9999 | F: +91 40 6692 9900
Email id: compliances@aragen.com, [website:www.aragen.com](http://www.aragen.com)

Extract of consolidated financial results for the quarter and year ended 31 March 2023 (₹ in million)

S. No.	Particulars	Quarter ended				For the Year ended	
		31		31		31	31
		March 2023	December 2022	March 2022	March 2023	March 2022	
1.	Total Income from operations	4,353.98	4,515.65	3,654.16	17,366.01	13,873.61	
2.	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary Items)	871.97	822.09	650.50	3,065.50	2,673.66	
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	871.97	822.09	650.50	3,065.50	2,673.66	
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	640.63	601.17	500.15	2,198.71	1,974.63	
5.	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	870.21	648.60	440.84	2,031.62	1,968.75	
6.	Paid up Equity Share Capital (Face value of Rs. 10/- each)	2,044.14	681.38	681.38	2,044.14	681.38	
7.	Reserves (excluding Revaluation Reserve)	9,707.37	10,204.86	9,640.54	9,707.37	9,640.54	
8.	Securities Premium Account	-	391.33	391.33	-	391.33	
9.	Net worth	11,751.51	10,886.24	10,321.92	11,751.51	10,321.92	
10.	Paid up Debt Capital/ Outstanding Debt	6,286.30	6,361.10	6,204.64	6,286.30	6,204.64	
11.	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.	N.A.	
12.	Debt Equity Ratio*	0.45	0.49	0.50	0.45	0.50	
13.	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid)						
14.	Basic EPS (Rs)	3.44	7.81	7.33	10.72	9.73	
15.	Diluted EPS (Rs)	3.40	7.72	7.25	10.59	9.62	
16.	Capital Redemption Reserve	-	3.36	3.36	-	3.36	
17.	Debiture Redemption Reserve	200.00	200.00	200.00	200.00	200.00	
18.	Debt Service Coverage Ratio*	0.99	1.17	1.56	3.10	4.71	
19.	Interest Service Coverage Ratio*	12.85	9.07	7.46	8.88	12.37	

Notes:

- *Quarter ended ratios are not annualised. *EPS not annualised for the quarter ended.
- The above is an extract of the detailed format of quarterly/annual financial results prepared in accordance with the Indian Accounting Standards (Ind AS) filed with the stock exchange under Regulation 52 of the Listing Regulations as the Company's debt securities (Non-convertible Debenture (NCD) of ₹ 2,000 million with annual interest rate of 7.75% and secured by first charge on property at the Malappuram unit with minimum asset cover of 1.25x) are listed on any Stock Exchange.
- For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed @ www.bseindia.com
- The above financial results have been reviewed and recommended by the Audit Committee at its meeting held on 23 May 2023 and approved by the Board of Directors at its meeting held on 24 May 2023.
- The full format of the quarterly/annual financial results including detailed notes thereon are available on the websites of the stock exchange, BSE Limited at www.bseindia.com and the Company at www.aragen.com
- The statutory auditors of the Group have carried out an audit of the above consolidated financial results for the quarter and year ended 31 March 2023 and have issued an unmodified audit report. The audit report of the Statutory auditor was filed with the BSE Limited and also is available on the Company's website.
- Figures for the quarter ended 31 March 2023 and 31 March 2022 represents the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial years.
- On 13 December 2021, the Group has acquired 56.82% of equity stake in Intox Private Limited ("Intox"). The acquisition was executed through a share purchase agreement ("SPA") and the Group has also agreed to acquire the balance stake up to 100% in a phased manner. As per the terms of SPA, the Group has control over 76% of the equity interest of Intox with purchase consideration to be paid in two tranches. The Group has paid the tranche-I consideration during the previous year and further paid the balance tranche-II during current year.
- The Company has issued bonus equity shares of Rs. 10/- (Rupees Ten) of every fully paid-up Equity Shares in proportion of 2 (two) new fully paid-up Equity Shares of Rs. 10/- (Rupees Ten) for every 1 (One) existing fully paid-up Equity Shares of Rs. 10/- (Rupees Ten) each to the eligible shareholders and the published unaudited year to date figures up to 27 January 2023. Consequent to this bonus issue, the earnings per share has also been adjusted for all the previous periods presented, in accordance with Ind AS 33, Earnings per Share.
- The Board of Directors of the Company have recommended a final dividend of ₹2.65 per share on 24 May 2023 for the financial year ended 31 March 2023. Such final dividend is subject to approval of the shareholders.
- During the quarter and year ended 31 March 2023, the Company had not received any complaints from the NCD holders and there has been no complaint pending for redressal at the beginning or at the end of the quarter.

For Aragen Life Sciences Limited
S/-
Manmohesh Kantipudi
Whole Time Director & CEO
DIN: 05241166

Date: 24th May 2023
Place: Hyderabad